Retrieve available abstracts of 31 articles: HTML format
Single Articles
December 2025
SCHOENFELD JD, Haas-Kogan DA, O'Neill AF Abscopal response in a patient with fibrolamellar hepatocellular carcinoma
following radiotherapy.
Lancet. 2025;404:2603-2604. PubMed
May 2025
VITHAYATHIL M, Sharma R Nivolumab plus ipilimumab in hepatocellular carcinoma.
Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417. PubMed
YAU T, Galle PR, Decaens T, Sangro B, et al Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment
for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label,
randomised, phase 3 trial.
Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403. PubMedAbstract available
February 2025
RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al Pregnancy and the liver.
Lancet. 2025;405:498-513. PubMedAbstract available
January 2025
REITER FP, Geier A TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular
carcinoma.
Lancet. 2025 Jan 8:S0140-6736(24)02680-1. doi: 10.1016/S0140-6736(24)02680. PubMed
SANGRO B, Kudo M, Erinjeri JP, Qin S, et al Durvalumab with or without bevacizumab with transarterial chemoembolisation in
hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind,
placebo-controlled, phase 3 study.
Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551. PubMedAbstract available
KUDO M, Ren Z, Guo Y, Han G, et al Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab
versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma
(LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575. PubMedAbstract available
November 2024
ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al Steatotic liver disease.
Lancet. 2024;404:1761-1778. PubMedAbstract available
October 2024
PONVILAWAN B, Roth MT Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
Lancet. 2024;404:1405. PubMed
QIN S Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial
- Author's reply.
Lancet. 2024;404:1405-1406. PubMed
WANG JK, Liao R Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
Lancet. 2024;404:1404-1405. PubMed
LI H, Yan J, Han T Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
Lancet. 2024;404:1403-1404. PubMed
September 2024
ADAM R, Piedvache C, Chiche L, Adam JP, et al Liver transplantation plus chemotherapy versus chemotherapy alone in patients
with permanently unresectable colorectal liver metastases (TransMet): results
from a multicentre, open-label, prospective, randomised controlled trial.
Lancet. 2024;404:1107-1118. PubMedAbstract available
HEINEMANN V, Stintzing S Liver transplantation in metastatic colorectal cancer: a new standard of care?
Lancet. 2024;404:1078-1079. PubMed
TANAKA A, Ma X, Takahashi A, Vierling JM, et al Primary biliary cholangitis.
Lancet. 2024;404:1053-1066. PubMedAbstract available
August 2024
MAIWALL R, Kulkarni AV, Arab JP, Piano S, et al Acute liver failure.
Lancet. 2024;404:789-802. PubMedAbstract available
CHOW PKH, Hack SP, Spahn JH, Yopp AC, et al Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors'
reply.
Lancet. 2024;404:657-658. PubMed
ROSE S, Ashraf MU, Premkumar M Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
Lancet. 2024;404:656-657. PubMed
CHEN Z, Lan X, Du C, Xiao H, et al Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
Lancet. 2024;404:656. PubMed
DONADON M, Di Martino M, Rigamonti C Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
Lancet. 2024;404:655-656. PubMed
SHIN H, Lee JH Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
Lancet. 2024;404:654-655. PubMed
June 2024
ENG C, Yoshino T, Ruiz-Garcia E, Mostafa N, et al Colorectal cancer.
Lancet. 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360. PubMedAbstract available
May 2024
DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al Invasive liver abscess syndrome with central nervous system involvement caused by
hypermucoviscous Klebsiella pneumoniae: positive string test.
Lancet. 2024;403:2257-2258. PubMed
April 2024
KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al The EASL-Lancet Commission on liver health in Europe: prevention, case-finding,
and early diagnosis to reduce liver-related mortality.
Lancet. 2024;403:1522-1524. PubMed
November 2023
VON KODOLITSCH Y, Kubisch C, Carrel T AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
Lancet. 2023;402:1626. PubMed
KUEPPERS F AATD as a genetic risk factor for aneurysmal disease.
Lancet. 2023;402:1625-1626. PubMed
October 2023
VOGEL A, Meyer T, Saborowski A IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962. PubMed
QIN S, Chen M, Cheng AL, Kaseb AO, et al Atezolizumab plus bevacizumab versus active surveillance in patients with
resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a
randomised, open-label, multicentre, phase 3 trial.
Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796. PubMedAbstract available
September 2023
PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al The price and value of therapeutic synergy in liver cancer.
Lancet. 2023;402:1108-1110. PubMed
TAPPER EB, Serper M Screening for advanced liver disease in the general population.
Lancet. 2023;402:941-943. PubMed
SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al Development, validation, and prognostic evaluation of a risk score for long-term
liver-related outcomes in the general population: a multicohort study.
Lancet. 2023;402:988-996. PubMedAbstract available